<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238742</url>
  </required_header>
  <id_info>
    <org_study_id>2017ZDSYLL025-P01</org_study_id>
    <nct_id>NCT03238742</nct_id>
  </id_info>
  <brief_title>The Efficacy of Xuebijing Injection on Sepsis</brief_title>
  <official_title>The Efficacy of Xuebijing Injection in Adult Patients With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Family Planning Commission, P.R.China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Chasesun Pharmaceutical Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Efficacy of Xuebijing Injection in Adult Patients with Sepsis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this placebo-controlled study is to determine if Xuebijing Injection treatment
      provides significant mortality reduction improvement in patients with sepsis compared with
      placebo treatment in patients receiving the current standard of care for sepsis. This study
      will also assess the effectiveness of Xuebijing Injection in reducing 28-day mortality in
      patients with sepsis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind (Participant, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>28 Days after randomization</time_frame>
    <description>Death from all causes at 28-days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 Days after randomization</time_frame>
    <description>Subgroup stratified analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate in ICU</measure>
    <time_frame>90 Days after randomization</time_frame>
    <description>Survival rate at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 days Mortality</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>All-cause mortality rate at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate at hospital discharge</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality rate at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 1,4,7,28 after randomization</time_frame>
    <description>Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score at 1, 4, 7, and 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHEⅡ</measure>
    <time_frame>Day 1,4,7,28 after randomization</time_frame>
    <description>APACHEⅡat 1, 4, 7, and 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disseminated intravascular coagulation score</measure>
    <time_frame>Day 1,4,7,28 after randomization</time_frame>
    <description>Disseminated intravascular coagulation score at 1, 4, 7, and 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Duration of mechanical ventilation in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CRRT</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Duration of CRRT in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Duration of stay in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>1,4,7days after randomization</time_frame>
    <description>C-reactive protein at 1, 4,7days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin</measure>
    <time_frame>1,4,7 days after randomization</time_frame>
    <description>Procalcitonin at 1,4,7days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet</measure>
    <time_frame>1,4,7 days after randomization</time_frame>
    <description>Platelet at 1, 4,7days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>1,4,7 days after randomization</time_frame>
    <description>Prothrombin time at 1, 4,7days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>1,4,7 days after randomization</time_frame>
    <description>Activated partial thromboplastin time at 1, 4,7days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma fibrinogen</measure>
    <time_frame>1,4,7 days after randomization</time_frame>
    <description>Plasma fibrinogen at 1, 4,7days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>1,4,7 days after randomization</time_frame>
    <description>D-dimer at 1, 4,7 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human leukocyte antigens-D-related</measure>
    <time_frame>1,4,7 days after randomization</time_frame>
    <description>Human leukocyte antigens-D-related 1,4,7 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living (ADL)</measure>
    <time_frame>6，12 Months after randomization</time_frame>
    <description>Activities of daily living (ADL) after 6， 12 Months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100ml Xuebijing Injection will be dissolved in 100 mL of 0.9% normal saline every 12 hours for 5 days in a single-blind fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% normal saline 200 mL every 12 hours for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xuebijing Injection</intervention_name>
    <description>100ml Xuebijing Injection every 12 hours for 5 days</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% normal saline</intervention_name>
    <description>200ml 0.9% normal saline every 12 hours for 5 days</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be eligible for inclusion if all of the inclusion criteria are met

          1. Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of
             Intensive Care Medicine (ESICM)

          2. 18≤ age ≤75years

          3. 2 ≤SOFA ≤13

          4. obtain informed consent

        Exclusion Criteria:

          1. 48 hours after diagnosis of sepsis

          2. Pregnancy or lactating

          3. Body weight index &lt;18.5 or &gt;30

          4. Severe Primary disease such as uncontrolled and metastasis malignancy, hematopathy,
             HIV

          5. Severe, preexisting, parenchymal liver dysfunction or kidney dysfunction with SOFA≥3

          6. Previous immunodepressant Within 6 months before study entry or Receipt of a
             solid-organ or bone marrow transplant

          7. Previous glucocorticosteroid Within 7 days before study entry, more than
             Methylprednisolone (or convert to Methylprednisolone) ≥20mg/day

          8. Participation in an investigational clinical trial within 30 days

          9. Cannot finish the study (Expected survival &lt; 48 hours or refuse treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiu Haibo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southeast University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Songqiao, Dr.</last_name>
    <phone>+8613770723635</phone>
    <email>lsongqiao@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongda Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu songqiao, Dr</last_name>
      <phone>+862583262550</phone>
      <email>108422934@qq.com</email>
    </contact>
    <investigator>
      <last_name>Songqiao Liu, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Songqiao Liu</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Xuebijing Injection, morality, sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Mortality</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>2</doc_id>
      <doc_type>Clinical Review&amp; Education</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/26903338</doc_url>
      <doc_comment>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC.The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

